The approval by the HSE of a new treatment option for people with breast cancer at high-risk of recurrence, which could reduce the chance of their cancer returning by 30%, has been welcomed as a "significant milestone".
The drug, known as abemaciclib and manufactured by pharmaceutical company Eli Lilly, will be given to people with high-risk oestrogen-driven breast cancer.
According to oncologists, oestrogen-driven breast cancer is the most common type, making up around 70% of all cases, and in around a quarter of these, there is a high risk of the cancer returning.
The drug will be administered as a tablet and will be given for two years to eligible patients.
It will be available from 1 June.
'Significant milestone': HSE approves breast cancer drug
The approval by the HSE of a new treatment option for people with breast cancer at high-risk of recurrence, which could reduce the chance of their cancer returning by 30%, has been welcomed as a "significant milestone".
